Search - tctmd.com

Displaying 261 - 280 of 324

Sort: Relevancy | Date

Presentation ECHO 2017

Echocardiolgraphy in Hypertrophic Cardiomyopathy

Presenter: Linda D. Gillam

April 01, 2017

Presentation ECHO 2017

Echocardiography in the Management of Patients With Left Ventricular Assist Devices

Presenter: Michael H. Picard

March 31, 2017

Presentation ECHO 2017

Doppler Echocardiography Hemodynamic Assessment

Presenter: Jae K. Oh

March 31, 2017

Presentation ECHO 2017

Echo Hemodynamics II: Echo Quantification of Valvular Regurgitation

Presenter: Linda D. Gillam

March 31, 2017

News Daily News

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

Michael O'Riordan

March 29, 2017

News Conference News ACC 2017

MitraClip Commercial Experience at 1 Year Sheds Light on Progress and Lingering Concerns

L.A. McKeown

March 27, 2017

News Daily News

MitraClip for Tricuspid Regurgitation Gains Traction but Still in Preliminary Stages

Yael L. Maxwell

March 27, 2017

News Conference News ACC 2017

My Takeaways From ACC 2017: Even With a Sea Change, the Tide Takes Its Time

Shelley Wood

March 23, 2017

News Conference News ACC 2017

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

Yael L. Maxwell

March 23, 2017

News Conference News ACC 2017

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Michael O'Riordan

March 21, 2017

News Conference News ACC 2017

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

Michael O'Riordan

March 19, 2017

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

News Conference News ACC 2017

FFR-Guided Complete Revascularization Tops PCI of Culprit Artery Alone in Acute STEMI

Todd Neale

March 18, 2017

News Conference News ACC 2017

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

Michael O'Riordan

March 18, 2017

News Conference News ACC 2017

Live From Washington: ACC 2017, Day Two

Shelley Wood

March 18, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

Presentation CHIP Washington DC 2017

Hemodynamics and PCI: Case Presentation

Presenter: Ajay J. Kirtane

March 16, 2017

News Daily News

Fish Oils: Yes for HF and Secondary Prevention, No for the General Population, Says AHA

Michael O'Riordan

March 15, 2017

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Shelley Wood

March 10, 2017

Presentation SIF 2017

Complex Multivessel Intervention

Presenter: Manish A. Parikh

March 10, 2017

Advertisement

Echocardiolgraphy in Hypertrophic Cardiomyopathy

Echocardiography in the Management of Patients With Left Ventricular Assist Devices

Doppler Echocardiography Hemodynamic Assessment

Echo Hemodynamics II: Echo Quantification of Valvular Regurgitation

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

MitraClip Commercial Experience at 1 Year Sheds Light on Progress and Lingering Concerns

MitraClip for Tricuspid Regurgitation Gains Traction but Still in Preliminary Stages

My Takeaways From ACC 2017: Even With a Sea Change, the Tide Takes Its Time

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

FFR-Guided Complete Revascularization Tops PCI of Culprit Artery Alone in Acute STEMI

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

Live From Washington: ACC 2017, Day Two

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Hemodynamics and PCI: Case Presentation

Fish Oils: Yes for HF and Secondary Prevention, No for the General Population, Says AHA

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Complex Multivessel Intervention

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content